Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04497662 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects
A Phase 1 study, sponsored by Kiniksa Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT04497662 is a Phase 1 study that has completed, run by Kiniksa Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT04497662, a Phase 1 study, has completed, sponsored by Kiniksa Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
Phase 1, randomized, double-blind, placebo-controlled first-in-human study to investigate the safety, tolerability, PK and PD properties of single ascending intravenous (IV) and subcutaneous (SC) doses of KPL-404 in healthy subjects
Interventions
- OTHER Matching Placebo
- DRUG KPL-404
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-10-22 |
| Est. Completion | 2021-03-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04497662
The ClinicalTrials.gov registry entry for NCT04497662 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kiniksa Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT04497662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04497662 about?
NCT04497662 is a clinical study titled "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects". Phase 1, randomized, double-blind, placebo-controlled first-in-human study to investigate the safety, tolerability, PK and PD properties of single ascending intravenous (IV) and subcutaneous (SC) doses of KPL-404 in healthy subjects
What is the current status of trial NCT04497662?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2019-10-22. Estimated completion is 2021-03-02.
What interventions are being tested in trial NCT04497662?
The interventions under investigation include: Matching Placebo (OTHER), KPL-404 (DRUG).
Who is sponsoring clinical trial NCT04497662?
This trial is sponsored by Kiniksa Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.